Search
Use the filters to narrow by type of content
Looking for a Publication? Search the bibliography for: publications understanding treatment preferences patients kras pg12clc1 mk2 ��� mutated advanced non
… Integrated Real-World Clinical and Economic Evaluation of Treatment Alternatives OPPORTUNITY Disease-modifying … of various DMTs for MS. CHALLENGE Analyses of comparative treatment effectiveness—such as studies that evaluate data … design and conduct a comparative effectiveness analysis of treatment alternatives in MS that explicitly accounted for …
… on projects to research respiratory disease, respiratory treatment, and complications and comorbidities of respiratory … treat respiratory diseases and complications arising from treatment of respiratory illnesses. Benefit-risk preference …
… be introduced in January 2025 for new oncology medicines, advanced therapies (also known as cell and gene therapies), … have first-hand experience with the IRA and an in-depth understanding of the EU HTAR, including the JCAs and joint … disease burdens, unmet medical needs, and patient preferences. We support clinical trial design by …
… score? The RTI Rarity tool merges artificial intelligence, advanced data science methods, and geospatial analytics in a … private datasets from publicly available federal, state, non-profit, and academic resources, including: US Census …
Market Access and Outcomes Strategy You need the right strategies and tactics to reflect your product’s value and gain market access. And when millions—or maybe billions—are on the line, you have to be confident that your strategies are well-researched …
… Reported Share on: August 25, 2016 About one-third of patients with ADHD have an inadequate response to initial stimulant treatment and consequently might be considered for treatment with one of two second-line treatment …
… the inclusion of clinical data affect planned or pending publications? Manufacturers should determine the appropriate … attributes. Takeaway 6: Consider developing a section on treatment landscape and unmet need Although not specified in … guidance for development of a UPD or UUD, describing the treatment landscape for the indication can help the payer …
… Many HTA agencies make specific statements about their preferences for health utility measures, but their guidelines … weights are not available, outcomes may be valued using preferences that reflect the general population with … comprising the collection of health state data from patients via a generic questionnaire and the valuation of …
… be introduced in January 2025 for new oncology medicines, advanced therapies (also known as cell and gene therapies), … have first-hand experience with the IRA and an in-depth understanding of the EU HTA Regulation, including the JCAs … disease burdens, unmet medical needs, and patient preferences. We support clinical trial design by …
… Identifying Psychosis in Patients with Dementia: Not a Hallucination or Delusion, the … Share on: August 22, 2019 Identifying Psychosis in Patients with Dementia: Not a Hallucination or Delusion, the … other types of dementia. Antipsychotics are a second-line treatment for this condition, but an increased mortality has …